NCT07830199
A Clinical Study of SHR-4595 Injection in Patients With Advanced Solid Tumors to Evaluate Safety, Tolerability and Pharmacokinetics
StatusRecruiting
PhasePhase 1
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below.
- Notable Recruitment opened
- Start date changed from estimate of Sep 2026 to Oct 20, 2026
- Site details revised at 2 of 2 sites
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Adverse events (AEs)
Timeframe: From Day 1 to 40 days after last dose.
Dose-limiting toxicity (DLT)
Timeframe: From Day 1 to 12 months.
Maximum Tolerated Dose (MTD)
Timeframe: From Day 1 to 12 months.
Recommended Phase 2 Dose (RP2D)
Timeframe: From Day 1 to 12 months.
Secondary (5)
Progression free survival (PFS)
Objective response rate (ORR)
Disease control rate (DCR)
Duration of response (DOR)
Overall survival (OS)
Arms and interventions
SHR-4595 GroupExperimental
SHR-4595 for Injection, in different stages with different doses.
Drugs: SHR-4595 for Injection
Sites
2 sites in 1 country